Equities analysts predict that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will report earnings of ($0.76) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Karyopharm Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.91). Karyopharm Therapeutics reported earnings per share of ($0.64) during the same quarter last year, which would suggest a negative year-over-year growth rate of 18.8%. The company is scheduled to report its next earnings results on Tuesday, August 14th.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full year earnings of ($3.03) per share for the current financial year, with EPS estimates ranging from ($3.40) to ($2.36). For the next year, analysts expect that the company will post earnings of ($2.91) per share, with EPS estimates ranging from ($3.56) to ($1.59). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.11). The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $4.59 million.
In other news, EVP Christopher Brett Primiano sold 2,000 shares of the firm’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $18.01, for a total value of $36,020.00. Following the completion of the transaction, the executive vice president now owns 675 shares in the company, valued at approximately $12,156.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $15.29, for a total value of $152,900.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares of the company’s stock, valued at approximately $7,983,566.47. The disclosure for this sale can be found here. Insiders sold a total of 62,000 shares of company stock valued at $996,220 in the last 90 days. 13.26% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $115,000. MetLife Investment Advisors LLC bought a new position in Karyopharm Therapeutics during the fourth quarter worth about $146,000. Two Sigma Investments LP grew its holdings in Karyopharm Therapeutics by 76.8% during the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after purchasing an additional 10,520 shares during the period. UBS Group AG grew its holdings in Karyopharm Therapeutics by 761.8% during the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after purchasing an additional 17,354 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in Karyopharm Therapeutics during the first quarter worth about $269,000. Institutional investors own 61.90% of the company’s stock.
Shares of Karyopharm Therapeutics traded up $0.54, reaching $18.04, during trading hours on Thursday, MarketBeat reports. The company had a trading volume of 341,944 shares, compared to its average volume of 607,152. The company has a market cap of $849.94 million, a P/E ratio of -6.42 and a beta of 3.73. Karyopharm Therapeutics has a 1-year low of $8.00 and a 1-year high of $20.39.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.